本帖最后由 老马 于 2013-3-13 13:43 编辑 Y4 i! W, o. w- X
/ k7 ^7 i6 z: z. A3 \/ U健择（吉西他滨）+顺铂+阿瓦斯汀; S* N2 h0 o) b! ~' I( T& ?
Gemzar +Cisplatin + Avastin8 Q! v- }: H$ n, a; c
http://annonc.oxfordjournals.org/content/21/9/1804.full0 W' k. X; y' l+ U" c& u9 n
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
9 W6 C% t& @4 q. TPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. , M+ z; Q0 C- S& A
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 3 J: D& b5 T" k' U1 f9 l0 o
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 284)
1 r) h8 d) h' A+ O& _0 L华为网盘附件：
/ ~, H. R' y" C) E& J+ ^【华为网盘】ava.JPG9 }$ B0 w: h% ?! y. \& W2 d
|
显身卡
